Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
lunes, octubre 26
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Corcept Therapeutics Inc
CORT
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$85.86
-21.64
-20.13%
Últ. Act.: Oct 23, 7:41 PM
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Corcept Therapeutics Financials
Corcept Therapeutics (CORT) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Corcept Therapeutics (CORT) Stock Soars 22% After Hours: Here's What You Need To Know
Corcept Therapeutics shares soared 21.95% after hours as strong quarterly results and raised guidance boosted investor confidence.
Mohd Haider
PRO
Corcept Therapeutics Raises FY2026 Sales Guidance from $950.000M-$1.050B to $1.100B-$1.200B vs $1.008B Est
Corcept Therapeutics (NASDAQ:CORT) raises FY2026 sales outlook from $950.000 million-$1.050 billion to $1.100 billion-$1.200 billion vs $1.008 billion estimate.
Benzinga Newsdesk
PRO
Corcept Therapeutics Q2 EPS $0.36 Beats $(0.00) Estimate, Sales $256.147M Beat $219.988M Estimate
Corcept Therapeutics (NASDAQ:CORT) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate of $(0.00) by Infinity percent. This is a 24.14 percent increase over earnings of $0.29 per
Benzinga Newsdesk
Corcept Therapeutics Pivotal Study Shows 87% Lower Death Risk
Corcept shares rise after Phase 2 ALS data shows 87% lower death risk; earnings miss, revenue shortfall, and raised 2026 sales outlook.
Vandana Singh
PRO
Corcept Therapeutics Raises FY2026 Sales Guidance from $900.000M-$1.000B to $950.000M-$1.050B vs $941.180M Est
Corcept Therapeutics (NASDAQ:CORT) raises FY2026 sales outlook from $900.000 million-$1.000 billion to $950.000 million-$1.050 billion vs $941.180 million estimate.
Benzinga Newsdesk
PRO
Corcept Therapeutics Q1 EPS $(0.30) Misses $(0.16) Estimate, Sales $164.903M Miss $192.510M Estimate
Corcept Therapeutics (NASDAQ:CORT) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.16) by 87.5 percent. This is a 276.47 percent decrease over earnings of $0.17 per share
Benzinga Newsdesk
